|Title||In vitro generated human monoclonal trinitrophenyl-specific B cell lines. Evidence that human and murine anti-trinitrophenyl monoclonal antibodies cross-react with Escherichia coli beta-galactosidase.|
|Publication Type||Journal Article|
|Year of Publication||1987|
|Authors||Golding B, Inghirami G, Peters E, Hoffman T, Balow JE, Tsokos GC|
|Date Published||1987 Dec 15|
|Keywords||Animals, Antibodies, Monoclonal, B-Lymphocytes, Bacterial Proteins, beta-Galactosidase, Cell Line, Cell Transformation, Viral, Cross Reactions, Escherichia coli, Galactosidases, Herpesvirus 4, Human, Humans, Immunoglobulin kappa-Chains, Immunoglobulin M, Mice, Nitrobenzenes, Trinitrobenzenes|
Stable human antigen-specific monoclonal B cell lines were established without prior in vivo immunization. This was accomplished by expanding the anti-trinitrophenyl (TNP) B cells in vitro with the antigen TNP-Brucella abortus and then immortalizing them with Epstein-Barr virus. Five anti-TNP clones were selected by sequential limiting dilution. All five anti-TNP clones secreted IgM kappa antibodies. When tested against a panel of self and environmental antigens, all five anti-TNP clones exhibited cross-reactivity with an Escherichia coli-derived beta-galactosidase. To determine whether this was a more general phenomenon, a panel of murine monoclonals were tested and found to bind to beta-galactosidase. It is therefore possible that human and murine anti-TNP beta cell responses reflect reactivity against an environmental antigen, namely an epitope present on E. coli-derived beta-galactosidase. This approach of expanding human antigen-specific B cells by antigen stimulation in vitro, with a T-independent hapten-carrier conjugate before Epstein-Barr virus transformation, may prove useful in the development of human monoclonals for therapeutic purposes.
|Alternate Journal||J Immunol|
Giorgio Inghirami, M.D.